Method of Treating Medulloblastoma with an EZH2 Inhibitor


There is a long-felt yet unmet need for effective treatments for pediatric medulloblastoma, a cancer caused by genetic alterations or loss of function of subunits of the SWI/SNF chromatin remodeling complex that result in EZH2-dependent oncogenesis. Researchers at the University of Colorado have developed a method of treating a medulloblastoma in a pediatric subject by administering an enhancer of a zeste homolog 2 (EZH2) inhibitor such as Tazemetostat to prevent and/or inhibit proliferation of a medulloblastoma cell.

For Information, Contact:
Doreen Molk
University of Colorado
Rajeev Vibhakar
Disease Areas:
For inquiries, email:     © 2024. All Rights Reserved. Powered by Inteum